[go: up one dir, main page]

YU51101A - Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka - Google Patents

Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka

Info

Publication number
YU51101A
YU51101A YU51101A YUP51101A YU51101A YU 51101 A YU51101 A YU 51101A YU 51101 A YU51101 A YU 51101A YU P51101 A YUP51101 A YU P51101A YU 51101 A YU51101 A YU 51101A
Authority
YU
Yugoslavia
Prior art keywords
preparation
medicament
methods
producing same
telmisartan
Prior art date
Application number
YU51101A
Other languages
English (en)
Inventor
Heinrich Schneider
Original Assignee
Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh. & Co.Kg. filed Critical Boehringer Ingelheim Pharma Gmbh. & Co.Kg.
Publication of YU51101A publication Critical patent/YU51101A/sh
Publication of RS50044B publication Critical patent/RS50044B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Pronalazak se odnosi, na polimorfne oblike 4'-[2-n-propil-4-metil-6-(1-metilbenzimidazol-2-il)benzimidazol-1-ilmetil]bifenil-2-karbonske kiseline (INN: telmisartan), naročito na polimorfni oblik B (I), naznačen time, što se pri termičkoj analizi pomoću DSC javlja endotermni maksimum na 182В±2В°C, na smeše polimorfnih oblika, na postupak za pripremanje telmisartina koji sadrži oblik B, kao i na njegovu primenu u pripremanju leka.
YUP-511/01A 1999-01-19 2000-01-07 Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka RS50044B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19901921A DE19901921C2 (de) 1999-01-19 1999-01-19 Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels

Publications (2)

Publication Number Publication Date
YU51101A true YU51101A (sh) 2004-05-12
RS50044B RS50044B (sr) 2008-11-28

Family

ID=7894715

Country Status (36)

Country Link
EP (1) EP1144386B1 (sh)
JP (1) JP4700813B2 (sh)
KR (1) KR100658959B1 (sh)
CN (1) CN1144790C (sh)
AR (1) AR035475A1 (sh)
AT (1) ATE252564T1 (sh)
AU (1) AU765081B2 (sh)
BG (1) BG65027B1 (sh)
BR (1) BR0007584A (sh)
CA (1) CA2352436C (sh)
CO (1) CO5150238A1 (sh)
CZ (1) CZ297412B6 (sh)
DE (2) DE19901921C2 (sh)
DK (1) DK1144386T3 (sh)
EA (1) EA003065B1 (sh)
EE (1) EE04344B1 (sh)
ES (1) ES2208265T3 (sh)
HK (1) HK1041485B (sh)
HR (1) HRP20010514B1 (sh)
HU (1) HU227401B1 (sh)
IL (2) IL143634A0 (sh)
MY (1) MY122755A (sh)
NO (1) NO319823B1 (sh)
NZ (1) NZ513528A (sh)
PE (1) PE20001362A1 (sh)
PL (1) PL211829B1 (sh)
PT (1) PT1144386E (sh)
RS (1) RS50044B (sh)
SA (1) SA99200838B1 (sh)
SK (1) SK285429B6 (sh)
TR (1) TR200102074T2 (sh)
TW (1) TWI280241B (sh)
UA (1) UA56358C2 (sh)
UY (1) UY25980A1 (sh)
WO (1) WO2000043370A1 (sh)
ZA (1) ZA200104771B (sh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153737A1 (de) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
ES2445041T3 (es) 2002-01-16 2014-02-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Método para la preparación de telmisartán amorfo
DE10314702A1 (de) 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
CN101039917A (zh) 2004-10-15 2007-09-19 特瓦制药工业有限公司 制备替米沙坦的方法
WO2006044754A2 (en) 2004-10-18 2006-04-27 Dr. Reddy's Laboratories Ltd. Process for preparing telmisartan
US8637078B2 (en) 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
DE102008059206A1 (de) 2008-11-27 2010-06-10 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum
DK2432452T3 (en) 2009-05-20 2016-10-10 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutically telmisartan drink solution
WO2010146187A2 (en) 2009-06-19 2010-12-23 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
EP2632438A1 (en) 2010-10-27 2013-09-04 KRKA, tovarna zdravil, d.d., Novo mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
ITMI20102416A1 (it) * 2010-12-27 2012-06-28 Chemelectiva S R L Intermedio per la preparazione di un principio attivo e processo per la sua preparazione
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
JP6147546B2 (ja) * 2013-04-10 2017-06-14 株式会社トクヤマ 酢酸が低減されたテルミサルタンａ型結晶の製造方法
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
JP6275596B2 (ja) * 2014-09-03 2018-02-07 株式会社トクヤマ テルミサルタンのアンモニウム塩の製造方法
JP5871294B1 (ja) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
KR20170012703A (ko) 2015-07-22 2017-02-03 대원제약주식회사 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
US20200316029A1 (en) 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
KR102044223B1 (ko) * 2016-09-12 2019-11-13 성균관대학교산학협력단 텔미사르탄을 포함하는 고체 분산체 및 이의 제조방법
CN106749036B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用
CN106749037B (zh) * 2016-12-21 2019-06-21 山东大学 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用
LT3648761T (lt) 2017-07-07 2024-06-10 Boehringer Ingelheim Vetmedica Gmbh Telmisartanas, skirtas kačių hipertenzijos profilaktikai arba gydymui
CN109851562A (zh) * 2019-01-30 2019-06-07 浙江省食品药品检验研究院 一种替米沙坦晶体及其制备方法
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
AU2024276892A1 (en) 2023-05-24 2025-10-16 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of cardiac diseases in non-human mammals comprising one or more sglt-2 inhibitors and pimobendan and/or telmisartan
US20250195525A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9210098B (sl) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo
US5139114A (en) * 1991-03-18 1992-08-18 Abex Corporation Visible brake block wear indicator

Also Published As

Publication number Publication date
HUP0105148A3 (en) 2003-01-28
DE19901921A1 (de) 2000-08-03
RS50044B (sr) 2008-11-28
SK285429B6 (sk) 2007-01-04
CN1144790C (zh) 2004-04-07
CN1336920A (zh) 2002-02-20
IL143634A0 (en) 2002-04-21
KR100658959B1 (ko) 2006-12-19
ZA200104771B (en) 2002-12-02
BG65027B1 (bg) 2006-12-29
NZ513528A (en) 2003-08-29
CA2352436C (en) 2010-03-23
EA200100730A1 (ru) 2002-02-28
ATE252564T1 (de) 2003-11-15
CZ20012634A3 (cs) 2001-10-17
UA56358C2 (uk) 2003-05-15
WO2000043370A1 (de) 2000-07-27
EE04344B1 (et) 2004-08-16
TWI280241B (en) 2007-05-01
HU227401B1 (en) 2011-05-30
AU2288100A (en) 2000-08-07
SK10202001A3 (sk) 2001-12-03
HK1041485A1 (en) 2002-07-12
EP1144386A1 (de) 2001-10-17
MY122755A (en) 2006-05-31
BR0007584A (pt) 2001-11-06
HRP20010514A2 (en) 2002-08-31
DE50004150D1 (de) 2003-11-27
HK1041485B (zh) 2004-10-08
BG105654A (bg) 2002-01-31
PL211829B1 (pl) 2012-06-29
EP1144386B1 (de) 2003-10-22
JP2002535315A (ja) 2002-10-22
CO5150238A1 (es) 2002-04-29
PE20001362A1 (es) 2000-12-15
HUP0105148A2 (hu) 2002-07-29
HRP20010514B1 (en) 2010-01-31
EE200100375A (et) 2002-10-15
PT1144386E (pt) 2004-03-31
DE19901921C2 (de) 2001-01-04
AR035475A1 (es) 2004-06-02
UY25980A1 (es) 2001-08-27
EA003065B1 (ru) 2002-12-26
DK1144386T3 (da) 2004-01-12
ES2208265T3 (es) 2004-06-16
PL349425A1 (en) 2002-07-29
AU765081B2 (en) 2003-09-11
CA2352436A1 (en) 2000-07-27
SA99200838B1 (ar) 2006-03-06
NO319823B1 (no) 2005-09-19
JP4700813B2 (ja) 2011-06-15
KR20010101552A (ko) 2001-11-14
TR200102074T2 (tr) 2001-12-21
IL143634A (en) 2006-10-05
NO20013560D0 (no) 2001-07-18
CZ297412B6 (cs) 2006-12-13
NO20013560L (no) 2001-09-18

Similar Documents

Publication Publication Date Title
YU51101A (sh) Polimorfni oblici telmisartana, postupak za njihovo pripremanje i njihova primena za pripremanje leka
CA3160518C (en) GLP-1 RECEIVER AGONIST AND ITS USE
CU23105A3 (es) DERIVADOS NOVEDOSOS DEL áCIDO AMINODICARBOXILICO CON PROPIEDADES FARMACéUTICAS
AR029605A1 (es) DERIVADOS DE DIFENILUREA SUBSTITUIDOS CON SULFONAMIDA , COMPOSICIoN FARMACEUTICA , USO DE LOS MISMOS PARA LA MANUFACTURA DE UN MEDICAMENTO uTILES COMO ANTAGONISTA DE RECEPTORES DE IL-8, COMPUESTOS, INTERMEDIARIOS, Y MÉTODOS DE CONVERSIoN DE COMPUESTOS
TW200509914A (en) Pharmaceutical formulation of the telmisartan sodium salt
BR0113234A (pt) Polimorfos de um análogo de epotilona
BR0312513A (pt) Derivados de glicosìdeo de tiofeno, processos para a produção dos mesmos, medicamentos que contêm esses compostos e uso dos mesmos
BR0308212A (pt) Composto, composição farmacêutica, e, uso de um composto
GEP20012580B (en) Substituted 4-Hydroxy-Phenylalcanoic Acid Derivatives With Agonist Activity to PPAR-Gamma, Methods for Their Production, Pharmaceutical Conposition and Methods for Treatment
AR037148A1 (es) Sal sodica cristalina,procedimiento para su preparacion y su uso para la preparacion de un medicamento.
BRPI0409109A (pt) novos compostos
DE69928226D1 (de) Chemokin rezeptor antagonisten und verwndung
AR024440A1 (es) AGONISTAS DEL RECEPTOR A2A DE ETER PROPARGIL FENILICO, COMPOSICIoN FARMACEUTICA Y EL USO DE LOS MISMOS PARA PREPARAR UN MEDICAMENTO.
NO20044041L (no) Okso-azabisykliske forbindelser
BR0311189A (pt) Composições farmacêuticas contendo polimorfo a de flibanserin
AR033957A1 (es) Nuevos compuestos
BR9507231A (pt) Uso de derivados de ácido carboxílico para a produção de drogas
ES2191099T3 (es) Derivados de hidantoina como productos intermedios para principios activos farmaceuticos.
SE0101978D0 (sv) New compounds
MX2023012338A (es) Compuesto como antagonista del receptor de adenosina a2a y composicion farmaceutica que comprende al mismo.
AR029639A1 (es) Amidas sustituidas del acido fenilciclohexanocarboxilico, procedimiento para su preparacion, compuestos intermediarios, medicamentos, y el uso para la manufactura de un medicamento utiles como inhibidores de la incorporacion de adenosina
AR032711A1 (es) Derivados de fenilpiperazina, un metodo para la preparacion de los mismos y una composicion farmaceutica que los contiene
AR026241A1 (es) Empleo de carbinoles 2-imidazolil substituidos para la preparacion de un medicamento para el tratamiento o profilaxis de enfermedades provocadas porestados isquemicos
ECSP993250A (es) Polimorfos de telmisartan, procedimiento para su preparacion y su empleo para la preparacion de un medicamento
ES8701744A1 (es) Un procedimiento para la preparacion de una amina alilica